This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Larry C. Clark, MPH, PhD
University of Arizona Tucson

Gerald F. Combs, Jr, PhD; Bruce W. Turnbull, PhD; Elizabeth H. Slate, PhD
Cornell University Ithaca, NY

for the Nutritional Prevention of Cancer Study Group

JAMA. 1997;277(11):881.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—We share Dr Herbert's concern regarding the safety of using 200 µg of selenium in a high-selenium brewer's yeast and have been concerned about documenting both adverse and beneficial health effects of selenium supplementation, especially those that could only be identified in a doubleblind, placebo-controlled trial. The choice of a nutritional dose diminished the safety issues in the trial and was based on the upper limit of the US Estimated Safe and Adequate Intake of selenium.¹

The trial's Safety Monitoring Committee reviewed the incidence of patient-reported disease and did not identify any significant adverse health events associated with selenium supplementation. The trial eligibility criteria excluded patients with active liver and kidney disease; however, we have not identified any additional groups of patients in the trial who were at particular risk of adverse health events. For safety reasons, pregnant women were also excluded from active participation. While there may be . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?